A single institutional clinical outcome for stages III and IV ovarian cancer patients treated with dose‐dense TC therapy in the frontline or first platinum‐sensitive relapse setting

Documenti analoghi

• Establishment of a 3D spheroid culture system to evaluate the responsiveness of uterine leiomyoma cells to female hormones
  di: Takahiro Sakai, et al.
  Pubblicazione: (2025)
• Balancing ethics and clinical need: The Japanese experience with preimplantation genetic testing for monogenic disease regulation and implementation
  di: Kou Sueoka
  Pubblicazione: (2025)
• Predicting platinum resistance and poor prognosis in patients with epithelial ovarian cancer
  di: Maryam Amjad
  Pubblicazione: (2024)
• Establishment of Machine Learning Models for Estimating the Collagen Content of Uterine Leiomyomas and Prediction of the Effect of Gonadotropin‐Releasing Hormone Analog
  di: Tetsuro Tamehisa, et al.
  Pubblicazione: (2026)
• The efficacy, safety, and beneficiary population of angiogenesis inhibitor apatinib plus chemotherapy in recurrent platinum‐resistant ovarian cancer patients: A comparative cohort study
  di: Chunyan Wu, et al.
  Pubblicazione: (2024)